Dog Heartworm Disease: Medications, Prevention Brands, and Therapeutic Protocols

Introduction

Canine heartworm disease, caused by the filariid nematode Dirofilaria immitis, remains a globally significant vector-borne parasitic infection with substantial veterinary and zoonotic implications [1, 2, 3]. The parasite is transmitted through the bite of infected culicid mosquitoes, with over 70 species implicated as competent vectors worldwide [4, 5, 85]. In domestic dogs, adult worms reside in the pulmonary arteries and right ventricle, leading to progressive cardiopulmonary pathology, pulmonary hypertension, and, in severe cases, caval syndrome and death [57, 74, 89]. The disease is endemic in tropical, subtropical, and temperate regions, and its geographic range continues to expand due to climate change, vector invasion, and movement of infected reservoir hosts [6, 7, 8, 44, 73]. This article provides a detailed, evidence-based review of the pharmacological agents, preventive products, and therapeutic protocols employed in the management of canine heartworm disease, with an emphasis on biophysical mechanisms, clinical protocols, and current research findings.

Etiology and Life Cycle

Dirofilaria immitis (Spirurida: Onchocercidae) is a long, thin nematode with separate sexes; adult females measure 25–31 cm in length, and males 12–20 cm [9, 10]. The definitive host is the domestic dog, although the parasite can infect other canids, felids, and occasionally humans [11, 6, 12, 55, 79]. The life cycle involves mosquito intermediate hosts from genera such as Aedes, Culex, Anopheles, and Culiseta [5, 72, 85]. Ingested microfilariae (first-stage larvae, L1) develop within the mosquito Malpighian tubules into infective third-stage larvae (L3) over approximately 10–14 days, depending on ambient temperature [4, 85]. The L3 are transmitted to the canine host during subsequent blood meals [5]. After inoculation, L3 molt to L4 within 3–12 days and migrate through subcutaneous tissues, skeletal muscle, and connective tissue before entering the venous circulation [13, 14]. The final molt to young adult (L5) occurs approximately 50–70 days post-infection, and worms reach the pulmonary arteries by day 70–90 [13, 61, 81]. Adult worm maturation and patency (appearance of circulating microfilariae) typically occurs 6–7 months after infection [61, 81]. The obligate intracellular endosymbiont Wolbachia (order Rickettsiales) plays a critical role in worm embryogenesis, molting, survival, and host inflammatory response [15, 48, 50].

Pathophysiology and Clinical Presentation

The primary pathological target is the pulmonary arterial endothelium. Adult worms induce villous endarteritis, intimal proliferation, smooth muscle hypertrophy, and thrombus formation, leading to increased pulmonary vascular resistance and pulmonary hypertension [57, 74, 89]. Progressive vascular occlusion results in reduced cardiac output, right ventricular hypertrophy, and eventually right-sided congestive heart failure [57, 89]. Ectopic worm migration can occur into the pleural cavity, eye, central nervous system, or subcutaneous tissues [16, 17, 64, 77]. Caval syndrome (vena cava syndrome) is an acute, life-threatening condition caused by massive adult worm burden obstructing blood flow through the tricuspid valve and right atrium, manifesting as sudden collapse, hemoglobinuria, and hepatorenal failure [49, 57, 89].

Clinical staging of heartworm disease traditionally follows the American Heartworm Society (AHS) guidelines: Class 1 (mild, no or subclinical signs), Class 2 (moderate, cough, exercise intolerance), Class 3 (severe, dyspnea, cachexia, syncope), and Class 4 (caval syndrome) [43, 89]. Hematological alterations include thrombocytopenia, eosinophilia, basophilia, and increased haptoglobin concentrations [18, 63, 65]. Serum protein electrophoresis often reveals hyperglobulinemia with a polyclonal gammopathy [65]. Inflammatory markers such as tumor necrosis factor alpha (TNF-alpha) are elevated in infected dogs and may serve as adjunctive biomarkers for treatment monitoring [19]. Coinfections with other vector-borne pathogens (e.g., Ehrlichia spp., Anaplasma spp., Borrelia burgdorferi) are common and complicate diagnosis and management [2, 60, 84, 87, 90].

Diagnostic Approaches

Diagnosis relies on integrated serological and parasitological methods. Detection of circulating adult female worm antigen using commercial sandwich ELISA kits is the standard for routine screening, with high sensitivity (greater than 90%) for infections with one or more adult females [11, 20, 70]. Antigen tests detect only D. immitis; cross-reactivity with D. repens or Dipetalonema reconditum is minimal but documented [21, 9, 22, 68]. Microscopic identification of microfilariae on direct smear or modified Knott’s test remains important for differentiating D. immitis from Acanthocheilonema reconditum (formerly Dipetalonema reconditum) based on morphometric features and motility [2, 3, 58, 71]. Polymerase chain reaction (PCR) assays targeting mitochondrial cox1 or 12S rRNA genes provide species-level confirmation and can detect low-level parasitemia [2, 23, 66, 70, 86]. Quantitative real-time PCR can also assess Wolbachia loads [15]. Imaging modalities including thoracic radiography, echocardiography, and computed tomography aid in assessing disease severity and identifying caval syndrome [16, 57, 89]. Integration of serology, microscopy, and molecular diagnostics is recommended, particularly in regions where D. repens is co-endemic [21, 9, 22, 24, 68].

Therapeutic Protocols

The cornerstone of adulticidal therapy is the arsenical compound melarsomine dihydrochloride, administered as an intramuscular injection [25, 43, 59]. The standard three-dose protocol (2.5 mg/kg) involves an initial injection followed 30 days later by two injections 24 hours apart, which maximizes adulticide efficacy and reduces the risk of pulmonary thromboembolism [25, 43]. This protocol achieves complete adult worm clearance in approximately 90–95% of dogs [43]. Pre-treatment with a macrocyclic lactone (e.g., ivermectin, moxidectin) for 2–3 months is recommended to eliminate susceptible L3/L4 larvae and suppress microfilariae, reducing antigen load and inflammatory reactions following adulticide therapy [26, 27, 82]. Doxycycline (10 mg/kg twice daily for 28 days) is administered concurrently to deplete Wolbachia, leading to decreased worm viability and reduced post-adulticide inflammatory complications [15, 50]. Adjunct therapy includes strict exercise restriction, corticosteroids for severe pulmonary inflammation, and antithrombotics such as aspirin (controversial, not routinely recommended) [43, 57].

For dogs with caval syndrome, surgical extraction of adult worms via transvenous brush or forceps is indicated as a life-saving emergency intervention, after which medical adulticide therapy is completed [49, 57, 89]. The prognosis for surgically managed caval syndrome is fair to good if intervention occurs before irreversible organ damage [49].

Microfilaricidal therapy is required after adulticide treatment to eliminate circulating microfilariae. Macrocyclic lactones such as ivermectin (off-label at 50 mcg/kg orally) or milbemycin oxime (0.5 mg/kg) are effective and safe when administered after adult worm clearance [28, 29]. A single dose of moxidectin (2.5 mg/kg topical or injectable extended-release formulation) provides sustained microfilaricidal activity [26, 51, 82]. Adverse effects of microfilaricidal therapy, including shock-like reactions from rapid microfilarial killing, are mitigated by oral macrocyclic lactones with slower kill kinetics [28, 29].

The AHS protocol, when followed meticulously, yields excellent outcomes with manageable complications, primarily pulmonary thromboembolism and inflammatory reactions [43, 59]. Disseminated intravascular coagulation (DIC) is a rare but devastating complication following melarsomine therapy [59].

graph TD
    A[Diagnosis of D. immitis infection confirmed] --> B{Clinical Class}
    B -->|Class 1-3| C["Stabilize: exercise restriction, doxycycline 28 days"]
    C --> D[Macrocyclic lactone monthly for 2-3 months]
    D --> E[Melarsomine 3-dose protocol]
    E --> F["Post-adulticide monitoring: antigen test 6 months"]
    F --> G{Antigen negative?}
    G -->|Yes| H[Continue monthly prevention]
    G -->|No| I[Retreat with melarsomine]
    B -->|Class 4 (caval syndrome)| J[Emergency transvenous worm extraction]
    J --> K[Stabilize, then proceed to melarsomine protocol]
    I --> H
    K --> D

Prevention: Macrocyclic Lactone Agents and Combination Products

Prevention of heartworm disease relies on monthly administration of macrocyclic lactones (MLs) that target L3 and L4 larval stages, preventing maturation to adult worms [28, 29, 27]. Approved MLs include ivermectin (oral tablet or chewable), milbemycin oxime (oral chewable), moxidectin (topical or extended-release injectable), and selamectin (topical) [28, 29]. The extended-release injectable moxidectin formulation provides 12 months of protection with a single dose, but carries an FDA boxed warning for adverse events (including neurological signs) in collies and related breeds with MDR1 gene mutation; younger dogs of specific breeds are more susceptible to such events [51]. Ivermectin and milbemycin oxime have wider safety margins and are used in dogs as young as 6 weeks [28, 29].

Recent innovations include combination products that incorporate an ML with an isoxazoline ectoparasiticide, a taenicide, and/or a nematicide for broad-spectrum control of filarial worms, fleas, ticks, and gastrointestinal helminths. The combination of lotilaner (isoxazoline), moxidectin, praziquantel, and pyrantel (Credelio Quattro formulation) has demonstrated excellent efficacy in preventing D. immitis infection in dogs under field conditions, with no safety concerns in heartworm-positive dogs [30, 31]. A similar combination of milbemycin oxime and lotilaner (Credelio Plus) also shows high preventive efficacy and safety [82]. Another product combines afoxolaner, milbemycin oxime, and pyrantel for integrated flea, tick, heartworm, and hookworm control [26]. Extended-release moxidectin combined with fluralaner (Bravecto Plus) provides 6 months of tick and flea control plus heartworm prevention, although published safety data in heartworm-positive dogs are limited to single studies [28].

Compliance is a major determinant of preventive efficacy [27, 52, 56]. A retrospective analysis of veterinary practice data found that only 60–70% of dogs receive heartworm preventive year-round as recommended in endemic regions [56]. Factors associated with non-compliance include owner forgetfulness, cost, and perceived low risk [52, 56]. Integration of preventive medications with other routine veterinary visits and use of extended-release injectable formulations can improve adherence [27].

Macrocyclic Lactone Resistance: Emerging Threat

Resistance of D. immitis to MLs, particularly ivermectin and moxidectin, has been documented in isolates from the Mississippi Delta region of the United States and is a growing concern for prevention programs [32, 47]. Resistance is associated with specific single nucleotide polymorphisms (SNPs) in the P-glycoprotein (PGP) transporter gene and other efflux transporters, which reduce drug accumulation in the parasite [32, 47]. Comparative genomic analyses of resistant and susceptible isolates have identified candidate resistance loci, but the molecular mechanisms are multifactorial and not fully elucidated [10, 32, 47]. Population genomics studies suggest that resistant strains have persisted in refugia prior to widespread ML use, and that selection pressure from sustained ML prophylaxis has increased their frequency [10, 47]. In vitro screening of novel anthelmintics (e.g., emodepside) demonstrates high efficacy against ML-resistant D. immitis isolates, offering potential alternative prophylactic options [80]. Surveillance for resistance markers using molecular tools, such as droplet digital PCR for known SNPs, is recommended in endemic areas with suspected ML failures [32, 47].

Future Directions and Emerging Therapies

The development of safe, effective adulticides beyond melarsomine remains a critical research priority [25, 59, 80]. Newer macrocyclic lactone formulations with enhanced pharmacokinetics, such as high-dose moxidectin, are being evaluated for adulticidal activity, but robust clinical efficacy against mature adult worms has not been demonstrated in naturally infected dogs [26, 82]. Combination therapy with doxycycline and MLs reduces but does not eliminate adult worm burden unless treatment duration is extended [50]. Immunotherapeutic approaches targeting Wolbachia or parasite-specific antigens are in preclinical stages [48].

Non-invasive imaging (echocardiography, CT) continues to refine clinical staging and guide surgical extraction [16, 89]. The use of circulating microRNA profiles as biomarkers for early detection of infection and treatment monitoring is an area of active investigation [13, 81].

Conclusion

Canine heartworm disease remains a preventable but potentially fatal parasitic infection of global significance. Effective prevention relies on consistent use of macrocyclic lactone-based products, including novel combination formulations that improve compliance. The standard adulticide protocol with melarsomine, doxycycline, and strict exercise restriction remains the gold standard for treatment. Emerging ML resistance and the lack of new adulticides underscore the need for ongoing surveillance, research into alternative therapies, and robust client education. Integrated diagnostic algorithms combining antigen testing, microscopy, and molecular assays ensure accurate diagnosis and species differentiation from other filariids.

References

[1] Khalife S, El Safadi D. Canine vector-borne diseases in Lebanon: Unveiling prevalence trends and risk factors for public health and disease control. Vet Parasitol Reg Stud Reports. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42150803/

[2] Zanfagnini LG, Chocobar MLE, Schmidt EMS, et al. Unveiling filariid infections in dogs living in the Western Amazon, Brazil. Comp Immunol Microbiol Infect Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41818949/

[3] Roya GM, Yagoob G, Bahram AT. Seasonal study of blood parasites: Dirofilaria immitis and Dipetalonema reconditum in the guard dogs of Tabriz city, Iran. Arch Razi Inst. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41769291/

[4] Varga Z, Csiba R, Ábrahám Á, et al. Investigating the impact of endemic mosquitoes and invasive Aedes species on the circulation of Dirofilaria nematodes. Parasit Vectors. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40624566/

[5] Vismarra A, Genchi M, Maltoni A, et al. Preliminary data on the vector competence of Aedes caspius for Dirofilaria immitis in a traditionally endemic area of northern Italy. Parasit Vectors. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40474227/

[6] Dini FM, Musto C, Brogi R, et al. "Old hosts die hard": the return of the grey wolf (Canis lupus) and the re-emerging threat of cardiopulmonary dirofilariosis in northern Italy. Int J Parasitol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/40541602/

[7] Jerzsele Á, Kovács D, Fábián P, et al. New Insights into the Prevalence of Dirofilaria immitis in Hungary. Animals (Basel). 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40362013/

[8] Mõttus M, Mõtsküla PF, Jokelainen P. Heartworm disease in domestic dogs in Estonia: indication of local circulation of the zoonotic parasite Dirofilaria immitis farther north than previously reported. Parasit Vectors. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38475885/

[9] Ferraro E, Marchiori E, Dini FM, et al. Dirofilaria repens believed to be D. immitis: An erratic localization case in a golden jackal (Canis aureus). Int J Parasitol Parasites Wildl. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42011204/

[10] Power RI, Abdullah S, Walden HS, et al. Population genomics reveals an ancient origin of heartworms in canids. Commun Biol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41559308/

[11] Kim J, Kim M, Lee S, et al. Feline heartworm (Dirofilaria immitis) infection in stray cats in Ulsan, Korea. Parasites Hosts Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41668261/

[12] Kuthi L, Zombori T, Tiszlavicz L, et al. Emerging human pulmonary dirofilariasis in Hungary: a single center experience. Diagn Pathol. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38907257/

[13] Nakhale M, Hess JA, Oliver E, et al. Development of Dirofilaria immitis adult worms in NSG mice, detection of parasite-derived microRNA and comparative analysis of laboratory isolates. Sci Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41617897/

[14] Risch F, Ludwig-Erdmann C, Hoerauf A, et al. Development of adult Dirofilaria immitis worms in the Rag2/Il-2rγ(-/-) mouse model. Int J Parasitol. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38246406/

[15] Chu Y, Sakamoto K, Evans CC, et al. Real-time PCR and immunohistochemistry detection of Wolbachia in adult Dirofilaria immitis from dogs treated with doxycycline and ivermectin. Parasit Vectors. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40012073/

[16] Lim S, You M, Sohn S, et al. Computed tomographic and magnetic resonance imaging features of canine cervical epidural dirofilariasis. Vet Radiol Ultrasound. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39016074/

[17] Alonso FH, Shapiro K, Camp LE. Can nematode infection cause internal bleeding in dogs? A case of Dirofilaria immitis infection in cavitary fluids. Vet Clin Pathol. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38684482/

[18] Chocobar MLE, Eckersall DP, Panarese R, et al. Comparison of haptoglobin concentrations between microfilaremic and amicrofilaremic dogs infected by Dirofilaria immitis. Vet Clin Pathol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41612543/

[19] Spasojević Kosić L, Vracar V, Kozoderovic G, et al. Detection and dynamics of tumor necrosis factor alpha in the diagnosis and treatment of canine heartworm disease. Vet Ital. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38898794/

[20] Nelson CT, Johnson CM. Evaluation of feline heartworm disease based on gross necropsy, serology, pulmonary histopathology, and radiographic evidence in adult shelter cats in northeastern Alabama. Parasit Vectors. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38553770/

[21] Szabó KÉ, Aresu L, Müller L, et al. Clinico-pathological and renal morphological findings in dogs naturally infected with Dirofilaria repens. BMC Vet Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42069630/

[22] Rocha DODN, Macedo LO, Oliveira JCP, et al. Filarial nematodes in dogs from the Northeast region of Brazil. Acta Parasitol. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38536612/

[23] Roblejo-Arias L, Díaz-Corona C, Piloto-Sardiñas E, et al. First molecular characterization of Dirofilaria imm

[24] Perles L, Dantas-Torres F, Krücken J, et al. Zoonotic dirofilariases: one, no one, or more than one parasite. Trends Parasitol. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38228446/

[25] Still MB, Tedesco D, Hawkins C, et al. Improving access to melarsomine therapy: treating canine heartworm infection in a high-volume, outpatient community clinic setting. Parasit Vectors. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38459570/

[26] Drag M, Tielemans E, Mitchell E, et al. Safety of an oral combination of moxidectin, afoxolaner, and pyrantel pamoate in dogs. Res Vet Sci. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38631075/

[27] Mwacalimba K, Morrison JA, Ly P, et al. Prevention and long-term outcomes of naturally occurring canine heartworm infection in primary care settings. Front Vet Sci. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/38292131/

[28] Riepl M. Prophylaxis against heartworm infection and flea or tick infestation in dogs: Single agents and combination-drug products. Int J Pharm Compd. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38768502/

[29] Riepl M. Heartworm-, flea-, and tick-associated diseases in dogs: A review of common parasites and drug classes prophylactic against them. Int J Pharm Compd. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38768500/

[30] Young L, Reinemeyer CR, Abdelmoneim M, et al. Efficacy of a novel chewable tablet (Credelio Quattro) containing lotilaner, moxidectin, praziquantel, and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs. Parasit Vectors. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41943128/

[31] Riggs KL, Haney D, Wiseman S. Safety of Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) in dogs infected with adult heartworms (Dirofilaria immitis). Parasit Vectors. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40229900/

[32] Fisher PT, Keller K, Prichard RK. Investigating Dirofilaria immitis isolates infecting domestic canines and their susceptibility/resistance patterns to macrocyclic lactones in the northern region of the Mississippi Delta area (southeast Missouri). Vet Parasitol. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38781830/

[33] Montoya-Alonso JA, Balmori-de la Puente A, Costa-Rodríguez N, et al. A One Health perspective on heartworm disease: Allergy risk in owners of infected dogs in Gran Canaria (Spain). Animals (Basel). 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41227415/

[34] Colella V, Young ND, Manzanell R, et al. Dirofilaria asiatica sp. nov. (Spirurida: Onchocercidae) - Defined using a combined morphological-molecular approach. Int J Parasitol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40209888/

[35] Xhekaj B, Kniha E, Wiesmüller L, et al. Vector-borne pathogens in dogs from the Republic of Kosovo. Parasit Vectors. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40205569/

[36] Hopper RG, Ludwig AL, Salzman MM, et al. Effects of oral macrocyclic lactone heartworm preventatives on retinal function and chromatic pupillary light reflex in healthy companion dogs. Vet Ophthalmol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/39894736/

[37] Chocobar MLE, Schmidt EMDS, Mendes ÂJF, et al. Microgeographical variation in Dirofilaria immitis prevalence in dogs in suburban and urban areas of Rio De Janeiro, Brazil. Vet Sci. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39852878/

[38] Khouri NK, Singh S, Noble SAA, et al. Prevalence of Dirofilaria immitis in dogs in Jamaica. Parasitol Res. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39692786/

[39] Shirozu T, Regilme MAF, Ote M, et al. Wolbachia infection in Aedes aegypti does not affect its vectorial capacity for Dirofilaria immitis. Sci Rep. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39341970/

[40] Chocobar MLE, Schmidt EMDS, Weir W, et al. The distribution, diversity, and control of dirofilariosis in Brazil: A comprehensive review. Animals (Basel). 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39272246/

[41] Williams LBA, Buswell ML, Perisho NA. First autochthonous case of Angiostrongylus vasorum in a domestic dog in the United States. J Am Vet Med Assoc. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39094624/

[42] Mohammadkhani M, Abdi N, Sharifi-Sarasiabi K. Human dirofilariasis infection in the forehead: A case report. Iran J Public Health. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/38435762/

Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.